文献速递慢性肾脏病

免疫激活生物标志物与需要替代治疗的肾衰竭发生:AASK研究

Biomarkers of Immune Activation and Incident Kidney Failure With Replacement Therapy: Findings From the African American Study of Kidney Disease and Hypertension.
PubMed 文献 · Am J Kidney Dis · 2021-01-01

该研究基于AASK前瞻性队列中500例非糖尿病肾病的非洲裔美国人,随访中位9.6年,发现基线sTNFR1、sTNFR2和TNF-α水平与需替代治疗的肾衰竭(KFRT)风险独立相关,sTNFR1、sTNFR2和TNF-α亦与全因死亡相关,而IFN-γ与两种结局均无关。

要点

  • sTNFR1、sTNFR2、TNF-α与KFRT风险独立相关,每2倍升高风险分别增加3.66、2.29和1.35倍。
  • sTNFR1、sTNFR2、TNF-α与全因死亡显著相关,每2倍升高风险最高增加2.2倍。
  • IFN-γ与KFRT及死亡均无关联,且上述标志物未改变APOL1高风险状态与KFRT的关联。

核心结论

  • 在高血压所致CKD的非洲裔美国人中,基线sTNFR1、sTNFR2和TNF-α而非IFN-γ与KFRT及死亡相关。

研究设计与样本

  • 前瞻性队列,纳入AASK研究中500例有基线血清样本的参与者。

主要发现

  • 中位随访9.6年,发生161例(32%)KFRT和113例(23%)死亡。
  • 校正人口学、临床因素及基线肾功能后,sTNFR1每2倍升高KFRT风险增加3.66倍(95%CI 2.31-5.80),sTNFR2增加2.29倍(95%CI 1.60-3.29),TNF-α增加1.35倍(95%CI 1.07-1.71)。
  • sTNFR1、sTNFR2和TNF-α亦与死亡显著相关(每2倍升高风险最高增加2.2倍,P≤0.01);IFN-γ与两种结局均无关。
  • 上述生物标志物均未改变APOL1高风险状态与KFRT的关联(交互作用P>0.05)。

临床怎么用

  • 在非糖尿病肾病的非洲裔美国人中,检测sTNFR1、sTNFR2和TNF-α可能有助于识别KFRT和死亡高风险者。

局限性

  • 结果对其他种族或CKD病因的普适性有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

RATIONALE & OBJECTIVE: Immune activation is fundamental to the pathogenesis of many kidney diseases. Innate immune molecules such as soluble urokinase-type plasminogen activator receptor (suPAR) have been linked to the incidence and progression of chronic kidney disease (CKD). Whether other biomarkers of immune activation are associated with incident kidney failure with replacement therapy (KFRT) in African Americans with nondiabetic kidney disease is unclear. STUDY DESIGN: Prospective cohort. SETTING & PARTICIPANTS: African American Study of Kidney Disease and Hypertension (AASK) participants with available baseline serum samples for biomarker measurement. PREDICTORS: Baseline serum levels of soluble tumor necrosis factor receptor 1 (sTNFR1), sTNFR2, tumor necrosis factor α (TNF-α), and interferon γ (IFN-γ). OUTCOMES: Incident KFRT, all-cause mortality. ANALYTICAL APPROACH: Cox proportional hazards models. RESULTS: Among 500 participants with available samples, mean glomerular filtration rate was 44.7mL/min/1.73m2, and median urinary protein-creatinine ratio was 0.09g/g at baseline. Over a median follow up of 9.6 years, there were 161 (32%) KFRT and 113 (23%) death events. In models adjusted for demographic and clinical factors and baseline kidney function, each 2-fold higher baseline level of sTNFR1, sTNFR2, and TNF-α was associated with 3.66-fold (95% CI, 2.31-5.80), 2.29-fold (95% CI, 1.60-3.29), and 1.35-fold (95% CI, 1.07-1.71) greater risks of KFRT, respectively; in comparison, each doubling of baseline suPAR concentration was associated with 1.39-fold (95% CI, 1.04-1.86) greater risk of KFRT. sTNFR1, sTNFR2, and TNF-α were also significantly associated with death (up to 2.2-fold higher risks per 2-fold higher baseline levels; P≤0.01). IFN-γ was not associated with either outcome. None of the biomarkers modified the association of APOL1 high-risk status (genetic risk factors for kidney disease among individuals of African ancestry) with KFRT (P>0.05 for interaction). LIMITATIONS: Limited generalizability to other ethnic groups or causes of CKD. CONCLUSIONS: Among African Americans with CKD attributed to hypertension, baseline levels of sTNFR1, sTNFR2, and TNF-α but not IFN-γ were associated with KFRT and mortality.

来源:Am J Kidney Dis,查看原文。版权归原作者所有。

引用

  1. Chen TK, Estrella MM, Appel LJ, et al. Biomarkers of Immune Activation and Incident Kidney Failure With Replacement Therapy: Findings From the African American Study of Kidney Disease and Hypertension. Am J Kidney Dis. 2021. PMID: 33388403. doi:10.1053/j.ajkd.2020.11.014

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。